Article Results (Showing 1 - 10 of 61) RSS Alert

Attention-Deficit Hyperactivity Disorder Market Forecast. 

M2 PRESSWIRE-20 October 2009-Research and Markets: Attention-Deficit Hyperactivity Disorder Market Forecast(C)1994-2009 M2 COMMUNICATIONS ...

News and FDA Updates for Impax Laboratories (NASDAQ:IPXL), American Medical Systems (Nasdaq:AMMD). 

M2 PRESSWIRE-2 October 2009-BiomedReports: News and FDA Updates for Impax Laboratories (NASDAQ:IPXL), American Medical Systems...

Letters to the editor 

Kids pushed too far Why are we surprised that college and, now, high school students are abusing "academic steroids" -- the amphetamine adderall...

Generics market becomes international as M&A activity intensifies 

Generics market becomes international as M&A activity intensifies.(Special Report: Generic Drugs) There's a paradox in the drug industry; as more...

Athletics: Gatlin wait for verdict 

OLYMPIC 100m sprint champion Justin Gatlin will have towait until June 6 to learn whether he will have the chance to defend his title in Beijing....

Shire's hyperactivity drug sales disappoint 

SHIRE fell 4pc after it said sales of Vyvanse, its new hyperactivitytreatment, would be at the lower end of City forecasts.

Britain's...

In brief: Sales rise 

BASINGSTOKE-BASED pharmaceutical firm Shire, which makes attention deficit hyperactivity drug Adderall, said full-year product sales rose 55%...

Bonde Do Role Marina Gasolina EP 

[ILLUSTRATION OMITTED] [ILLUSTRATION OMITTED] Bonde Do Role Marina Gasolina EP (Mad Decent) The juvenile mischief inherent to Bonde Do Role's...

Shire Q3 results fail to impress.(Financial report) 

Shire produced a bit each way for the market, and investors reacted likewise Richard Hemming Analysts waxed lyrical about Shire's...

IN BRIEF: Drugs lift 

DRUGS company Shire upped its 2007 expectations for revenue growth to 25% from 20%as it unveiled a 31% rise in second quarter revenues to...